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Abstract
Background: General practitioners (GPs) are ideally placed to bridge the widely noted evidence-
practice gap between current management of NVAF and the need to increase anticoagulant use to
reduce the risk of fatal and disabling stroke in NVAF. We aimed to identify gaps in current care,
and asked GPs to identify potentially useful strategies to overcome barriers to best practice.
Methods:  We obtained contact details for a random sample of 1000 GPs from a national
commercial data-base. Randomly selected GPs were mailed a questionnaire after an advance letter.
Standardised reminders were administered to enhance response rates. As part of a larger survey
assessing GP management of NVAF, we included questions to explore GPs' risk assessment,
estimates of stroke risk and GPs' perceptions of the risks and benefits of anticoagulation with
warfarin. In addition, we explored GPs' perceived barriers to the wider uptake of anticoagulation,
quality control of anticoagulation and their assessment of strategies to assist in managing NVAF.
Results: 596 out of 924 eligible GPs responded (64.4% response rate). The majority of GPs
recognised that the benefits of warfarin outweighed the risks for three case scenarios in which
warfarin is recommended according to Australian guidelines. In response to a hypothetical case
scenario describing a patient with a supratherapeutic INR level of 5, 41.4% of the 596 GPs (n = 247)
and 22.0% (n = 131) would be "highly likely" or "likely", respectively, to cease warfarin therapy and
resume at a lower dose when INR levels are within therapeutic range. Only 27.9% (n = 166/596)
would reassess the patient's INR levels within one day of recording the supratherapeutic INR.
Patient contraindications to warfarin was reported to "usually" or "always" apply to the patients of
40.6% (n = 242/596) of GPs when considering whether or not to prescribe warfarin. Patient refusal
to take warfarin "usually" or "always" applied to the patients of 22.3% (n = 133/596) of GPs. When
asked to indicate the usefulness of strategies to assist in managing NVAF, the majority of GPs
(89.1%, n = 531/596) reported that they would find patient educational resources outlining the
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benefits and risks of available treatments "quite useful" or "very useful". Just under two-thirds
(65.2%; n = 389/596) reported that they would find point of care INR testing "quite" or "very"
useful. An outreach specialist service and training to enable GPs to practice stroke medicine as a
special interest were also considered to be "quite" or "very useful" by 61.9% (n = 369/596) GPs.
Conclusion: This survey identified gaps, based on GP self-report, in the current care of NVAF.
GPs themselves have provided guidance on the selection of implementation strategies to bridge
these gaps. These results may inform future initiatives designed to reduce the risk of fatal and
disabling stroke in NVAF.
Background
Non-valvular atrial fibrillation (NVAF) is a common heart
arrhythmia, affecting one in 20 people over the age of 65
and one in ten over the age of 75 [1]. NVAF is a significant
risk factor for fatal and disabling ischaemic stroke [1] and
is implicated in about 15% of all ischaemic strokes and as
many as 30% of strokes occurring in people in their 80's
[2].
Level I evidence demonstrates that anticoagulation with
warfarin reduces the risk of stroke by 64% in relative terms
when compared with placebo [3] and by 39% when com-
pared with antiplatelets [4]. The absolute reduction in
stroke risk attributable to warfarin highlights the effective-
ness of anticoagulation, although the risk remains ele-
vated even with treatment. The annual risk of stroke for
people with NVAF at "high risk" ranges from 8.5% to
18.2% [5]. With warfarin, this risk can be reduced to
approximately 3% to 6.6% per year. Consequently, inter-
national guidelines, such as those conjointly published by
the American College of Cardiology, the American Heart
Association and the European Society of Cardiology [6],
recommend warfarin for NVAF, particularly for patients
who have more than one moderate risk factor (eg conges-
tive heart failure, hypertension, age greater than 75 years)
or who have "high risk" factors (previous stroke, TIA or
embolism).
Previous randomised controlled trials of anticoagulation
with warfarin, however, were limited as these were carried
out in specialist, tertiary centres, often recruiting younger
patients than those typically encountered in the primary
health care setting [3]. However, the recently published
Birmingham Atrial Fibrillation Treatment of the Aged
(BAFTA) trial demonstrated the effectiveness of warfarin
in routine clinical practice amongst an elderly cohort
(average 81.5 years) recruited and managed by GPs [7].
The results also indicated that warfarin was just as safe as
aspirin.
Opportunities for reducing stroke risk in people with
NVAF are frequently missed [8-10]. The National Institute
of Clinical Studies of Australia has summarised the large,
unrealised benefit of anticoagulation, stating: "For every
1000 people with atrial fibrillation given anticoagulants, 25
will avoid experiencing a stroke if they take oral anticoagulants
and 12 will avoid dying from a stroke" [11].
In general, implementation of evidence in practice is often
slow and incomplete. Knowledge gaps, organisational
constraints, cognitive biases during decision-making and
conservative attitudes towards behavioural change in
response to "new" evidence may prevent or attenuate
translation of evidence into practice [12]. There are spe-
cific barriers to the wider uptake of warfarin. Initiating
and maintaining patients on warfarin is a complex task
which presents several barriers for both GPs and patients.
First, the risk of stroke must be assessed to identify
patients in greatest need of anticoagulation [1,6]. Second,
the selection of appropriate management requires
rational consideration of the benefits and risks of treat-
ment. Third, effective therapeutic use of anticoagulation
requires regular blood monitoring of the international
normalised ratio (INR) and dose titration to maintain
therapeutic levels (2.0–3.0) [13]. Regular monitoring of
INR levels is required as foods rich in vitamin K and cer-
tain drugs interact with the anticoagulant effect of warfa-
rin. GPs must therefore ensure patients are tested regularly
and have mechanisms in place for providing timely feed-
back of results and immediate dosage titration when
required. Such requirements necessitate organisational
systems for patient recall as well as effective communica-
tion between GPs and patients to ensure patients under-
stand the importance of attending for regular monitoring.
Fourth, these and other barriers to the wider implementa-
tion of warfarin need to be overcome and strategies to
facilitate implementation must be feasible and acceptable
to GPs.
The management of atrial fibrillation remains sub-opti-
mal almost ten years since the publication of the first
meta-analysis evaluating the effectiveness of warfarin [3].
The current literature suggests that simply improving phy-
sician knowledge and raising awareness of the evidence
would be insufficient to remedy the evidence-practice gap.
Fears about the side-effects of warfarin appear to affect
physician prescribing. It has been shown that doctors
reduce their prescribing of warfarin after one of theirBMC Family Practice 2008, 9:62 http://www.biomedcentral.com/1471-2296/9/62
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patients with NVAF has been hospitalised for a major
bleeding event. However, rates of warfarin prescribing
remain unchanged after a patient with NVAF experiences
a stroke [10]. As discussed by others [10], these findings
suggest that physicians are uncomfortable with making
decisions that could actively induce harm. This contrasts
to committing "acts of omission" where adverse out-
comes, such as stroke, are less likely to be attributed to the
actions of a physician.
Patient factors are also relevant. In a review of eight stud-
ies assessing patient preferences [14], six studies reported
that fewer patients favoured warfarin compared with what
would have been expected if evidence-based recommen-
dations had been followed. However, results also indicate
patient willingness to take warfarin. In one study compar-
ing physician and patient preferences, patients had a
lower threshold for accepting warfarin, with patients
reporting that warfarin use is justified if 1.8 strokes in 100
people were avoided over two years [14]. By comparison,
physicians indicated that an average of 2.5 strokes would
need to be avoided over two years to justify warfarin.
Recent evidence indicates that patient preferences may be
affected by biases about warfarin which may not be
"rational". In a study evaluating a patient decision tool, a
significantly greater proportion of patients endorsed war-
farin when "blinded" to the drug name compared to when
the drug name was disclosed [15]. Qualitative research
with physicians also reports patient aversion to using war-
farin due to negative connotations [16].
To our knowledge, GPs have rarely been engaged in the
identification of barriers to managing NVAF, nor have
they been invited to comment on potentially useful strat-
egies to overcome barriers. Existing support for GPs to
appropriately manage NVAF and stroke risk has not been
assessed. As part of a larger national survey [17], we
assessed GPs' perceptions about the risks and benefits of
warfarin and the services available to them to better man-
age NVAF. We sought GPs' views on strategies for better
managing NVAF.
Methods
Recruitment
The contact details of 1000 Australian GPs were randomly
selected from a commercial database [18]. The company
housing the commercial data-base reports wide coverage
and provides updated contact details. According to the
most recently available information (September 2008),
the commercial data-base had 22,669 doctors listed as
GPs [18]. The data-base sources contact details from, for
example, state medical registers, professional college and
society lists, postgraduate councils, and a national direc-
tory of medical practitioners in Australia. The Australian
Government Department of Health and Ageing listed
25,564 GPs in Australia in September 2007 [19]. How-
ever, the Department cautions that their headcount fig-
ures will overstate the number of active GPs [19]. It is our
understanding that the Australian Government does not
release mailing addresses of GPs to academic researchers,
preferring instead to carry out mail-outs "in-house". We
therefore opted for a list of GPs with updated contact
details from which we could directly contact the partici-
pants of the survey and administer reminders to improve
response rates.
Randomly selected GPs were mailed a questionnaire after
an advance letter. The survey was carried out from Octo-
ber 2005 until July 2006. Demographic and practice char-
acteristics have been reported elsewhere [17] and are
shown in Table 1 (additional file 1). Post code of practice
enabled us to determine the extent of socio-economic dis-
advantage of the area in which GPs served using a stand-
ardised index of relative socioeconomic disadvantage
(IRSD) widely implemented in Australian government
statistics and research [20]. The index of disadvantage
assigns decile scores ranking suburbs from the most (score
of 1) to the least socio-economic disadvantaged (score of
10). The score takes into account the prevalence of low
income, low educational attainment and unemployment
[20].
Survey items
As part of a larger survey [17], we explored issues relevant
to the diagnosis and management of NVAF as follows:
Risks assessment
GPs indicated the likelihood of performing nine tasks rel-
evant to assessing stroke risk in a 68 year old regular
patient without a history of prior stroke, newly diagnosed
with NVAF after a resting electrocardiogram (ECG) (Table
2, additional file 1). The identification of hypertension,
diabetes and congestive heart failure assists with the strat-
ification of stroke risk in people affected by NVAF
[1,5,21,22]. We therefore identified GPs who indicated
that they would be "highly likely" to assess blood glucose
levels, measure blood pressure and to carry out diagnostic
cardiac procedures (transthoracic echocardiogram, chest
x-ray or transoesophageal echocardiogram).
Estimate of stroke risk and the benefits of anticoagulation with 
warfarin
Three case scenarios were presented and GPs were asked
to estimate the number out of 100 people identical to
those described in each case who would experience a
stroke in 12 months' time (Table 3, additional file 1). For
each scenario, GPs indicated whether the "benefits of war-
farin outweigh the risks", "the benefits and risks of warfa-
rin are equally balanced", or "the risks of warfarin
outweigh the benefits". We referred to clinical risk stratifi-BMC Family Practice 2008, 9:62 http://www.biomedcentral.com/1471-2296/9/62
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cation schemes [1,5,21,22], including one local scheme
[1], to classify the risk of stroke as "moderate-low" (case
1) and "high" (cases 2 and 3). Evidence-based guidelines
advise that warfarin would optimise stroke risk reduction
for all three cases, although aspirin may also be suitable
for Case 1 [1].
Barriers
GPs were asked to consider seven reasons that might pre-
clude anticoagulation for patients with NVAF. GPs were
asked to estimate how often each reason applies to their
patients when considering whether or not to prescribe
warfarin. (Table 4, additional file 1).
Quality control of warfarin
GPs were presented with a case scenario of a "78 year old
patient diagnosed with NVAF" after a stroke who "has
recorded stable levels of INR within therapeutic range for
the previous three months" on warfarin. GPs indicated
how often they would measure INR levels and were asked
to specify the target level. GPs then indicated the likeli-
hood of enacting current guidelines for the management
of supra-therapeutic INR levels [13]. GPs indicated the
likelihood of ceasing "current warfarin therapy and
resume at a lower dose when INR levels are within thera-
peutic range" if this patient recorded an INR level of 5.0
with no evidence of bleeding on 8 mg of warfarin per day.
GPs were asked how many days after this consultation
they would reassess the patient's INR. Existing national
guidelines recommend reassessing INR levels within 24
hours of an abnormal result [13].
Strategies to assist in managing NVAF
GPs were asked to indicate the usefulness of strategies to
assist in managing NVAF (Table 5, additional file 1). The
strategies included practice resources (n = 6), training ini-
tiatives (n = 2), services (n = 5) and financial incentives (n
= 2).
Satisfaction with services
GPs rated their satisfaction with their access to services for
managing patients with stroke and at risk of stroke. (Table
4, additional file 1). Services included access to specialists
(n = 3), hospital services (n = 4) and diagnostic tests (n =
4).
Sample Size
We aimed to receive 600 questionnaires to estimate pro-
portions with a confidence interval not exceeding ± 2% of
the true value.
Analysis
Predictors of outcomes were identified using multivariate
logistic regression. Variables in Table 1 (additional file 1)
were identified as potential predictors in our multivariate
analyses and selected for screening to include in baseline
multivariate models. GP risk assessment, GPs' assess-
ments of whether the benefits of warfarin outweighed the
risks for each of the three case scenarios, and GPs' self-
reported quality control of warfarin were defined as out-
comes. Potential predictors with a bivariate association
with the outcome (p < 0.25) were entered into the model
and the least significant variable was successively removed
at each step until only significant predictors remained (p
< 0.05) [23]. Therefore, the results present adjusted odds
ratios in which the odds ratios were adjusted for the effects
of all other variables from Table 1 (additional file 1)
which remained significant (ie p < 0.05). All analyses were
carried out using SPSS for Windows (version 15.0.1.1)
[24].
Ethics approval
The study protocol was approved by The University of
New South Wales, Human Research Ethics Committee
(HREC# 05087).
Results
Response
Seventy-four doctors were ineligible because they were
not in general practice (n = 42), had retired (n = 11) or
died (n = 1), were ill (n = 2), could not be contacted (n =
3), were on extended leave (n = 12) or had left Australia
(n = 3). We received 596 questionnaires from 926 eligible
GPs (64.4%). Respondents appeared representative of
Australian GPs when compared with government statis-
tics, although full-time GPs were over-represented (Table
1, additional file 1). All percentages reported here are
based on a denominator of 596 unless otherwise indi-
cated.
Risk assessment
The majority of GPs stated that they would be "highly
likely" to auscultate the heart (86.9%) and measure the
blood pressure (90.9%) of a regular 68 year old patient
newly diagnosed with NVAF. Just over half (54.2%)
would be "highly likely" to determine blood glucose lev-
els while 22.8% and 30.7% would be "highly likely" to
refer the patient for a chest x-ray or transthoracic echocar-
diogram, respectively. Only 2.7% would be "highly likely"
to refer the patient for a transoesophageal echocardio-
gram (TOE) (see Table 2, additional file 1). Just under
one-third of GPs (32.4%) would be "highly likely" to refer
the patient to undergo a cardiac diagnostic test (either
chest x-ray or transthoracic echocardiogram or TOE), to
assess blood glucose levels and measure blood pressure,
which would potentially enable risk stratification of the
patient. Further, GPs who performed these diagnostic
tests were also significantly more likely to be "highly
likely" to refer the newly diagnosed patient to a specialist
(39.4% vs 25.6%) (χ2
(1) = 11.69) (p = 0.001). The numberBMC Family Practice 2008, 9:62 http://www.biomedcentral.com/1471-2296/9/62
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of years GPs had been practising was the only demo-
graphic and practice characteristic that significantly pre-
dicted whether or not GPs carried out relevant testing for
risk stratification. GPs who performed behaviours rele-
vant for risk stratification had been in general practice for
fewer years compared with those who did not (Mean =
17.8 years vs Mean = 19.6 years) (p = 0.046).
Estimates of stroke risk and the benefits of warfarin
When asked to consider 100 patients identical to the 65
year old patient at moderate to low risk of stroke depicted
in Case 1, the estimated median risk of stroke was 5% per
year (IQR = 2.5–10). This estimated median risk was sig-
nificantly lower than the estimated median risk for the 65
year old patient represented in Case 2 at high risk of stroke
(Median = 10, IQR = 6–20) (p < 0.0001) and for the 75
year old "high risk" patient (case 3) (Median = 10, IQR =
5–20) (p < 0.0001). There was no significant difference in
the median estimated risk of stroke between the patients
presented in Cases 2 and 3, who were both at high risk of
stroke (p = 0.09) (see Table 3, additional file 1).
Overall, 33.6% (n = 200) of GPs gave a correct estimate
for the annual stroke risk for the 65-year old patient with
a moderate to low risk of stroke presented in Case 1 (2–
5% per year). Just under one-quarter (23.8%; n = 142)
and 20.6% (n = 123) correctly estimated the annual stroke
risk for the 65-year old high risk patient depicted in Case
2 and for the high risk 75-year old patient depicted in Case
3 (6–12%). Most commonly, GPs reported that they did
not know the risk of stroke for each of the cases (n = 202,
33.9% for Case 1; n = 231, 38.8% for Case 2, and n = 232,
38.9% for Case 3). There was a tendency to be more likely
to over-estimate rather than under-estimate the risk of
stroke for Cases 1 and 2 (22.7% vs 9.4% for Case 1; 22.7%
vs 14.4% for Case 2). A similar proportion over- and
under-estimated the risk of stroke for Case 3 (21.8% vs
18.0%).
The majority of GPs indicated that the "the benefits of
warfarin outweigh the risks" for the 65-year old patient
depicted in Case 1 (n = 377, 63.3%) (Table 3, additional
file 1), although a significantly greater proportion indi-
cated that the "benefits of warfarin outweigh the risks" for
the 65 year old patient at "high risk" of stroke depicted in
Case 2 (63.3% vs 87.6%) (p < 0.001). Although the 75
year old patient depicted in Case 3 was also at high risk of
stroke, GPs were no more likely to indicate that the "ben-
efits of warfarin outweigh the risks" for this patient com-
pared with the patient represented in Case 1 (moderate to
low risk)(67.4% vs 63.3%) (p = 0.09), but were more
likely to indicate that the benefits of warfarin outweigh
the risks for the patient represented in Case 2 (87.6% vs
67.4%) (p < 0.0001).
Predictors of GPs indicating that the "benefits of warfarin 
outweigh the risks"
Male GPs and those practicing in less socio-economically
disadvantaged areas were significantly more likely to indi-
cate that the benefits of warfarin outweigh the risks for the
patient depicted in Case 1, at moderate to low risk of
stroke (Adjusted Odds Ratio (AOR) = 1.80, 95% CI =
1.26–2.58, p = 0.001 and AOR = 1.08, 95% CI 1.02–1.15,
p = 0.01, respectively). In addition, GPs with a full-time
nurse employed in their practice were significantly less
likely to indicate that the benefits of warfarin outweigh
the risks, compared with those who employed a part-time
nurse (AOR = 1.71, 95% CI 1.08–2.70) or those without
a nurse attached to their practice (AOR = 1.51, 95% CI
1.01–2.24) (p = 0.03).
We did not identify predictors of indicating that the ben-
efits of warfarin outweigh the risks for Case 2, as only
12.7% of GPs indicated otherwise in response to this sce-
nario.
GPs who were male, those practising in less socio-eco-
nomically disadvantaged areas and GPs who had partici-
pated in an education program about NVAF were all more
likely to report that the benefits of warfarin outweighed
the risks for the high risk patient presented in Case 3 (AOR
= 1.47, 95% CI 1.02–2.12, p = 0.04; AOR = 1.09, 95% CI
1.03–1.16, p = 0.004 and AOR = 1.60, 95% CI = 1.03–
2.48, p = 0.03, respectively).
Quality control of warfarin
Most GPs stated that they would measure INR levels
monthly (n = 463, 77.7%) for a 78 year old patient diag-
nosed with NVAF after a stroke who was currently receiv-
ing warfarin. Only 84 GPs (14.1%) would measure INR
levels fortnightly. Almost 90% of GPs selected a target INR
within the recommended range of 2.0–3.0 (n = 531,
89.1%) although 16.8% (n = 100) selected a target at the
lower end of this range (2.0–2.5). A small minority
selected a sub-therapeutic or supra-therapeutic target (n =
25, 4.2% and n = 34, 5.7%, respectively).
In response to an INR result of 5, 41.4% (n = 247) and
22.0% (n = 131) of GPs would be "highly likely" or
"likely", respectively, to enact current guidelines for man-
aging supra-therapeutic INR levels by ceasing warfarin
and resuming the drug at a lower dose when INR levels
became therapeutic [13]. However, 28.0% (n = 167)
would be "highly unlikely" or "unlikely" to enact current
guidelines in response to a supra-therapeutic INR.
Only 27.9% (n = 166) would reassess the patient's INR
within one day after the consultation, as recommended by
guidelines [13], while 32.2% (n = 192) of GPs would doBMC Family Practice 2008, 9:62 http://www.biomedcentral.com/1471-2296/9/62
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so after two days and 39.1% (n = 233) would reassess INR
levels three or more days after the consultation.
We classified GPs as adhering to evidence-based guide-
lines for the management of supra-therapeutic INR levels
if they would be "highly likely" or "likely" to enact guide-
lines for an INR of five and would reassess INR levels
within one day of the consultation. Only 21.8% of GPs (n
= 126) adhered to evidence-based guidelines when judged
against these criteria. Compared with GPs who worked
full-time, GPs who worked part-time were significantly
more likely to adhere to evidence-based guidelines (AOR
= 1.62, 95% CI = 1.05–2.48) (p = 0.03). Fewer years in
general practice (AOR = 0.96, 95% CI = 0.94–0.98) (p <
0.001) and practising in a less socio-economically disad-
vantaged suburb (AOR = 1.08, 95% CI = 1.01–1.16) (p =
0.03) were associated with an increased likelihood of
adhering to evidence-based guidelines.
Barriers to warfarin use
Contraindications to warfarin "usually" or "always"
applied to the patients of 40.6% of GPs (n = 242) when
considering whether or not to prescribe warfarin for their
patients with NVAF. One-third of GPs (31.0%) indicated
that this reason for not prescribing warfarin applied to
their patients "sometimes". Just under one-third of GPs
(32.7%) indicated that the "risk of adverse events will be
unacceptably high" "usually" or "always" precluded anti-
coagulation, while 39.8% (n = 237) indicated that this
reason "sometimes" applied to their patients.
Patients being at risk of falls was reported to "usually" or
"always" apply to the patients of 24.0% of GPs when con-
sidering whether or not to prescribe warfarin, with 49.2%
of GPs indicating that this "sometimes" applied to their
patients.
Almost 60% (59.1%) of GPs reported that patient inabil-
ity to comply with requirements for regular follow-up
"never" or "rarely" applied to their patients, with only
10% endorsing this reason as "usually" or "always" apply-
ing to their patients when they considered whether or not
to prescribe warfarin.
We had asked GPs to indicate how often patient reluc-
tance to take warfarin applied to their patients when mak-
ing decisions about warfarin. Just over two-thirds of GPs
(69.8%) indicated that this reason for not prescribing
warfarin applied to their patients at least "sometimes".
Just over one-half of GPs (52.7%) stated that patient
refusal precluded them prescribing warfarin at least
"sometimes" (Table 4, additional file 1).
Strategies for managing NVAF
Over 75% of GPs reported that patient education
resources, point of care INR testing and a computerised
risk calculator would be "quite" or "very useful" to assist
in managing NVAF (Table 5, additional file 1).
A computerised practice NVAF register, a practice nurse
and payments linked to preventive stroke management
for NVAF were strategies endorsed as "quite" or "very use-
ful" by 60% or more of GPs. An outreach specialist service
for GPs to phone, fax or email questions and training to
enable GPs to practice stroke prevention as a special inter-
est were similarly popular. A centralised register for NVAF,
anticoagulation clinics and pharmacist monitored INR
levels were amongst strategies considered "not useful" or
only "slightly useful" by more than 50% of GPs.
Satisfaction with services for managing stroke and patients 
at risk of stroke
The majority of GPs were either "satisfied" or "highly satis-
fied" with their access to diagnostic services (see Table 4,
additional file 1) with the exception of TOE (26.0%, n =
155). Compared with GPs located in capital cities or metro-
politan areas, GPs located outside these areas were signifi-
cantly less satisfied with their access to neurologists (50.7%
vs 29.8%), cardiologists (80.1% vs 88.5%), emergency
departments (65.5% vs 74.0%), stroke units (24.4% vs
40.4%), anticoagulation clinics (15.2% vs 26.4%), TOEs
(19.5% vs 28.8%), and 24 hour holter monitoring (83.0% vs
89.9%) (p's < 0.001 to 0.04). However, these GPs were more
likely to be "highly satisfied" or "satisfied" with their access
to a medical bed for acute stroke in their local hospital
(71.9% vs 56.0%) (p < 0.001).
Discussion
This national, representative survey offers insights into
how the evidence-based management of NVAF may be
best implemented. These results have identified gaps in
current practice that may be remedied by initiatives for
implementing the evidence.
While the importance of assessing hypertension in
patients with newly diagnosed NVAF was widely recog-
nised, the significance of other risk factors was less recog-
nised. While GPs could accurately determine that the risk
of stroke was higher for the "high risk" scenarios (Cases 2
and 3) compared with the lower risk scenario (Case 1),
GPs were no more likely to perceive that the benefits of
warfarin outweighed the risks for the high risk 75 year old
patient (case 3) compared with the lower risk 65 year old
patient (case 1). This result suggests wariness to anti-coag-
ulate aged patients, and demonstrates that concerns about
anticoagulation are not limited to the very elderly (>80
years of age). Gaps in GPs' self-reported management of
supra-therapeutic INR levels for patients using warfarin
were identified suggesting that the communication of
guidelines could be improved. More systematic dissemi-
nation and implementation of guidelines may be justi-
fied.BMC Family Practice 2008, 9:62 http://www.biomedcentral.com/1471-2296/9/62
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Our analysis has highlighted the challenges posed by Aus-
tralian general practice. Access to specialists, particularly
neurologists, does not appear to be satisfactory, and satis-
faction appears to have decreased compared with an ear-
lier survey [25]. Participation in educational programs
about stroke risk and NVAF predicted appropriate
appraisal of the risks and benefits of warfarin for the 75
year old patient at high risk of stroke, yet only 40% of GPs
thus far had been able to access programs about stroke
risk and only 25% had participated in programs about
NVAF.
Caseload may also be important. Male GPs were more
likely to identify when the benefits of warfarin out-
weighed the risks than female GPs. It is possible that
female GPs have limited opportunity to manage patients
with NVAF as they are more likely to practice part-time
when compared with male GPs [19]. It was difficult to
assess the independent effect of gender and part-time
practice in our analysis because of the strong correlation
between the two variables. Although NVAF accounts for a
significant proportion of all strokes [2], the prevalence of
NVAF is low [1] and the absolute numbers of patients
with NVAF within individual practices may therefore be
small. Therefore, male GPs may have greater experience in
decision-making about NVAF, which may result in
improved confidence about using warfarin. The survey
may have also captured gender differences in risk seeking
behaviour or risk aversion [26], although research on risk
attitudes in physicians does not necessarily demonstrate
gender differences [27,28]. As we did not directly assess
these constructs we cannot speculate further on whether
attitudes towards risk influenced our findings.
GPs whose practices were located in areas of greater soci-
oeconomic disadvantage were less likely to endorse warfa-
rin for patients either at "high" or "moderate to low risk"
and were less likely to report behaviour indicating adher-
ence to guidelines for managing supra-therapeutic INR
levels. In Australia, residents in these areas are more likely
to be born overseas and are less fluent in English than
areas with less socioeconomic disadvantage [29]. This
may limit GPs' ability to effectively engage their patients
in discussions about the benefits and risks of warfarin for
NVAF and reduce GP confidence in managing the condi-
tion. Moreover, residents in areas of greater socio-eco-
nomic disadvantage have high rates of other stroke risk
factors, such as hypertension, smoking, diabetes and
obesity [30-33]. The management of these more prevalent
conditions may displace the focus on NVAF.
The availability of a part-time nurse or no access to a prac-
tice nurse and fewer years in general practice were also
associated with GPs' perceived benefits and risks of warfa-
rin. The reason for this association is unclear, although
practice nurses may be employed for specialist tasks.
Therefore, this variable may be a proxy indicator for those
GPs who have special interests that reflect particular
strengths in clinical areas that are not relevant to stroke or
aged care. In our survey, we found that a full-time nurse
was more likely to be employed by GPs who indicated
having a special interest in providing services for minor
surgery (data not shown), giving some support for this
interpretation.
In addition to fewer years in general practice, working
part-time was also found to be associated with evidence-
based self-reported management of supra-therapeutic INR
levels. GPs who worked part-time were more likely to
report behaviour indicating adherence to guidelines for
managing supra-therapeutic INRs. These GPs may have
less opportunity for following up patients and be more
likely to institute immediate action because they may oth-
erwise be unable to rectify supra-therapeutic INR levels.
Alternatively, GPs who work part-time may be more likely
to work in larger group practices and will therefore have
the capacity to refer patients for follow-up compared with
GPs who work full-time. GPs who work full-time may give
consideration to providing continuity of care themselves,
which may result in delaying the reassessment of INR lev-
els. These explanations remain untested, however.
Fewer years in general practice predicted GP assessment of
how the benefits and risks of warfarin are balanced as well
as their self-reported management of supra-therapeutic
INR levels. This result may reflect a cohort effect where
more recently trained GPs may be more skilled in the
principles of evidence-based medicine. This exposure dur-
ing medical and post-graduate training may increase con-
fidence in accessing and applying guidelines in their
practice. However, we did not collect data to support this
interpretation.
GPs indicated strategies that they would find most useful
to assist them to manage NVAF. Practice tools and
resources were favoured by the majority of GPs. These
strategies can be easily incorporated within general prac-
tice and provide assistance with a broad spectrum of tasks
ranging from risk assessment, patient tracking, treatment
decision-making and the quality control of anticoagula-
tion. Services that were located outside the practice were
not favoured. The one exception was an outreach special-
ist service. GPs also favoured training sufficient to enable
them to practice stroke medicine as a special interest,
although special interest practices in stroke medicine do
not currently exist in the Australian primary health care
setting. An outreach service, if established, may be used to
facilitate such training as well as improve access to special-
ists in stroke medicine.
Patient refusal or reluctance to take warfarin, was nomi-
nated to at least "sometimes" apply to the patients ofBMC Family Practice 2008, 9:62 http://www.biomedcentral.com/1471-2296/9/62
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more than half of the GPs surveyed. Other studies directly
eliciting patient preferences have demonstrated that
patient views about warfarin may indeed limit the wider
uptake of warfarin [14]. Protheroe et al found that almost
40% of the 260 patients surveyed with atrial fibrillation
aged 70–85 years preferred not to receive anticoagulation
[34]. A recently reported randomised controlled trial com-
pared guideline recommendations to a computerised
decision-aid outlining the benefits and harms of warfarin
individualised to a patient's own stroke risk [35]. One-
quarter of patients receiving the decision-aid who were
not already receiving warfarin started anticoagulation
therapy, compared with 94% of those not already on war-
farin receiving the evidence-based guidelines. It is impor-
tant to note here that the existing literature on patient
preferences is likely to be out of date as recent evidence
from the BAFTA study [7] indicates the efficacy and safety
of warfarin compared with aspirin. This new evidence
may change the perceived benefit-harm trade-offs.
Another study has found that patients themselves have a
strong aversion to the name "warfarin"and are more likely
to endorse warfarin when "blinded" to the name [15].
Even so, our results suggest that GPs often confront the
real tension between a patient's preference to avoid anti-
coagulation, and perhaps their own willingness to pre-
scribe warfarin to reduce the risk of fatal and disabling
stroke. GPs themselves have indicated the importance of
taking into account patient values [16]. Many GPs may be
accepting of a patient's decision not to take warfarin,
emphasising the importance of respecting patient values.
Others have expressed concern that the way in which they
framed the benefits and risks may have contributed to
patients making "the wrong decision" [16]. While out-
comes evaluating patient decision tools include knowl-
edge and decisional conflict [36], the question of whether
these tools reduce the experience of regret in the event of
an "avoidable stroke" or "avoidable serious bleeding"
remains unanswered.
More than 80% of GPs in this study nominated patient
educational resources outlining the "pros and cons of
available treatment" as either quite or very useful. While
the evidence suggests that these resources may not pro-
mote sustained wider uptake of warfarin [36], these may
nonetheless promote shared decision-making between
GPs and their patients, improve patient understanding
and assist with clarifying patient values.
Limitations
While our relatively high response rate maximises the rep-
resentativeness of findings, care in interpreting self-
reported data is always required. Non-responders may
have differed from responders in ways that we could not
ascertain. Therefore, it is possible that our results would
have differed if we had achieved a higher response rate.
Moreover, our results may also be sensitive to the way in
which we measured GP adherence to evidence-based
guidelines and the criteria against which we judged GPs'
responses. It must also be acknowledged that self-reported
data may not faithfully reflect what GPs actually do when
managing atrial fibrillation in their practice. Therefore,
the difficulties in determining the validity of self-reported
findings apply here. Further, these results may not be gen-
eralisable to other practising clinicians, such as cardiolo-
gists or neurologists, who are likely to manage relatively
high numbers of patients with atrial fibrillation.
The survey itself was quantitative, and did not provide the
opportunity for GPs to elaborate on their given responses.
For example, the influence of case scenarios on decision-
making was assessed using a quantitative approach which
enabled us to determine how many GPs tip the balance in
favour for or against warfarin. However, such an approach
does not allow us to determine which aspects of the
patient history GPs relied upon when assessing the clini-
cal histories presented in the case scenarios. A qualitative
approach would have also allowed greater latitude in
introducing co-morbidities and other relevant aspects of a
patient's medical history and invite discussion into how,
for example, a history of bleeding or a history of falls
would impact on decision-making.
Other issues relevant to GPs' adherence to guidelines were
not assessed. Previous studies indicate that GPs may be
sceptical of the evidence supporting the use of warfarin
because of the select patient groups targeted in earlier ran-
domised trials of warfarin [16]. While the results of the
BAFTA study carried out in general practice with elderly
patients (Mean age 81 years) had not yet been reported at
the time of our survey [7], it remains to be seen whether
the results of this trial will allay GPs' concerns about the
limited generalisability of earlier studies. Other factors
which could potentially influence warfarin uptake include
the reluctance of GPs to challenge decisions made by
medical specialists and concerns about liability should
adverse events occur as a result of changing specialist rec-
ommendations [16]. Normative beliefs about what col-
leagues might or might not do may also be influential
[16].
Our survey items for risk assessment and case scenarios
were based on local evidence-based guidelines which pro-
vided estimates of actual stroke risk against which GP esti-
mates could be compared. We acknowledge that other
guidelines do not include TOE assessment for risk stratifi-
cation and risk assessment [5,6]. However, transoesopha-
geal findings, such as spontaneous echo contrast, have
been shown to increase stroke risk [37], and were incorpo-
rated into guidelines that existed at the time our survey
was conducted [1].BMC Family Practice 2008, 9:62 http://www.biomedcentral.com/1471-2296/9/62
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Conclusion
Recent evidence identifies general practice as an appropri-
ate and safe context in which to manage patients with
NVAF [7]. This representative survey has alerted us to gaps
in current care and GPs themselves have guided us on
which implementation strategies are acceptable to reduce
the risk of fatal and disabling strokes in people with
NVAF.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
JW approached the other researchers with the idea of car-
rying out a research project about the management of
NVAF in general practice. All authors contributed to the
development of the questionnaire, questionnaire items
and the interpretation of results. MG carried out the sur-
vey, analysed data and wrote the first draft of the manu-
script. All others critically reviewed and edited the
manuscript and MG revised the paper in response to feed-
back from other authors. All authors read and approved
the final manuscript.
Additional material
Acknowledgements
The authors express their gratitude to Ms Tracey Coles for administering 
advance letters to general practitioners and for her diligent data entry. We 
also thank Ms Maria-Jose Velasco for her diligent double data entry of all 
questionnaires to maximise data quality. A posthumous acknowledgement 
is extended to Dr Ian W Black for being involved in the formation of this 
study. Dr Melina Gattellari was supported by a Post-doctoral Public Health 
Training Fellowship from the National Health and Medical Research Coun-
cil of Australia (Reg Key #300616) at the time of carrying out the study and 
is now supported by a Commonwealth Department of Health and Ageing 
Primary Health Care Research, Evaluation and Development Mid-Career 
Fellowship. Melina Gattellari was named as the principal investigator on an 
Early Career Researcher grant awarded from the Faculty of Medicine, The 
University of New South Wales to carry out this study; all other authors 
were associate investigators.
References
1. Hankey GJ: Non-valvular atrial fibrillation and stroke preven-
tion.  Medical Journal of Australia 2001, 174:234-348.
2. Wolf P, Singer D: Preventing stroke in atrial fibrillation.  Am
Fam Phys 1997, 56:2242-2250.
3. Hart RG, Pearce LA, Aguilar MI: Meta-analysis: Antithrombotic
therapy to prevent stroke in patients who have nonvalvular
atrial fibrillation.  Annals of Internal Medicine 2007, 146:857-867.
4. Hart RG, Pearce LA, Aguilar MI: Adjusted-dose warfarin versus
aspirin for preventing stroke in patients with atrial fibrilla-
tion.  Annals of Internal Medicine 2007, 147:590-592.
5. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford
MJ: Validation of clinical classification schemes for predicting
stroke: results from the national registry of atrial fibrillation.
JAMA 2001, 285:2864-2870.
6. American College of Guidelines for the Management of
Patients with Atrial Fibrillation: a report of the American
College of Cardiology/American Heart Association.  Circula-
tion 2006, 114:e257-354.
7. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Mur-
ray E, BAFTA investigators. Midland Research Practices Network
(MidReC): Warfarin versus aspirin for stroke prevention in an
elderly community population with atrial fibrillation (the
Birmingham Atrial Fibrillation Treatment of the Aged
Study, BAFTA): a randomised controlled trial.  Lancet 2007,
370:493-503.
8. Birman-Deych E, Radford MJ, Nilasena DS, Gage BF: Use and effec-
tiveness of warfarin in Medicare beneficiaries with atrial
fibrillation.  Stroke 2006, 37:1070-1074.
9. O'Donnell M, Oczkowski W, Fang J, Kearon C, Silva J, Bradley C,
Guyatt G, Gould L, D'Uva C, Kapral M, Silver F: Investigators of
the Registry of the Canadian Stroke Network. Preadmission
antithrombotic treatment and stroke severity in patients
with atrial fibrillation and acute ischaemic stroke: an obser-
vational study.  Lancet Neurology 2006, 5(9):749-54.
10. Choudhry NK, Anderson GM, Laupacis A, Ross-Degnan D, Normand
SLT, Soumerai SB: Impact of adverse events on prescribing
warfarin in patients with atrial fibrillation: matched pair
analysis.  British Medical Journal 2006, 332:141-145.
11. National Institute of Clinical Studies: Evidence-practice gaps
report. A review of developments 2004–2007.  Canberra:
National Health and Medical Research Council 2008, 1: [http://
www.nhmrc.gov.au/nics/asp/index.asp?page=knowledge/
knowledge_article_type&cid=5212&id=406].
12. Grol R, Grimshaw J: From best evidence to best practice.  Lancet
2003, 362:1225-1230.
13. Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM:
Warfarin reversal: consensus guidelines, on behalf of the
Australasian Society of Thrombosis and Haemostasis.  MJA
2004, 181(9):492-497.
14. Man-Son-Hing M, Gage BF, Montgomery AA, Howitt A, Thomson R,
Devereaux PJ, Protheroe J, Fahey T, Armstrong D, Laupacis : Prefer-
ence-based antithrombotic therapy in atrial fibrillation:
implications for clinical decision-making.  Medical Decision Mak-
ing 2005, 25:548-559.
15. Holbrook A, Labiris R, Goldsmith CH, Ota K, Harb S, Sebaldt RJ:
Influence of decision aids on patient preferences for antico-
agulant therapy: a randomized trial.  Canadian Medical Associa-
tion Journal 2007:1583-7.
16. Lipman T, Murtagh MJ, Thomson R: How research conscious GPs
make decisions about anticoagulation in patients with atrial
fibrillation: a qualitative study.  Family Practice 2004, 21:290-298.
17. Gattellari M, Worthington J, Zwar N, Middleton S: Barriers to the
use of anticoagulation for nonvalvular atrial fibrillation: a
representative survey of Australian family physicians.  Stroke
2008, 39:227-30.
18. Australasian Medical Publishing Company Direct: Doctor and
health-care lists.   [http://www.ampcodirect.com.au/].
19. Australian Government Department of Health and ageing: General
Practice Statistics.   [http://www.health.gov.au/internet/main/pub
lishing.nsf/Content/health-pcd-programs-gpstats-explan.htm].
20. Australia Bureau of Statistics. 2033.0.55.001: Census of Population
and Housing: Socio-Economic Indexes for Areas (SEIFA),
Australia – Data only 2006.   [http://www.abs.gov.au/ausstats/
abs@.nsf/Latestproducts/2033.0.55.001Main%20Features99992006?
opendocument&tabname=Summary&prodno=2033.0.55.001&issue=
2006&num=&view=].
21. McAlister FA, Man-Son_Hing M, Straus SE, Ghali WA, Gibson P,
Anderson D, Cox J, Fradette M, the Decision Aids in Atrial Fibrillation
(DAAFI) Investigators: A randomized trial to assess the impact
of an antithrombotic decision aid in patients with nonvalvu-
lar atrial fibrillation: the DAAFI trial protocol
[ISRCTN14429643].  BMC Cardiovascular Disorders 2004, 4:5.
Additional file 1
Tables 1–5
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2296-9-62-S1.doc]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Family Practice 2008, 9:62 http://www.biomedcentral.com/1471-2296/9/62
Page 10 of 10
(page number not for citation purposes)
22. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE:
Antithrombotic therapy in atrial fibrillation.  Chest 2001,
119:194-206.
23. Hosmer DW, Lemeshow S: Applied logistic regression.  Brisbane;
John Wiley and Sons; 2001. 
24. Norusis MJ: SPSS for Windows, Rel. 15.0.1.1. 2007.  Chicago:
SPSS Inc. 
25. Middleton S, Harris JP, Sharpe DM, Corbett AJ, Lusby RJ, Ward JE:
Improving stroke outcomes in NSW: A study of GP perspec-
tives.  Australian Journal of Primary Health 2004, 10:21-28.
26. Rosen AB, Tsai JS, Downs Sm: Variations in risk attitude across
race, gender and education.  Medical Decision Making 2003,
23:511-7.
27. Baldwin RL, Green Jw, Shaw JL, Simpson DD, Bird TM, Cleves MA,
Robbins JM: Physician risk attitudes and hospitalization of
infants with bronchiolitis.  Academic Emergency Medicine 2005,
12:142-6.
28. Nakata Y, Okuno-Fujiwara M, Goto T, Morita S: Risk attitudes of
anaesthesiologists and surgeons in clinical decision making
with expected years of life.  Journal of Clinical Anesthesia 2000,
12:146-50.
29. Australian Bureau of Statistics: 2006 Census Data.   [ h t t p : / /
www.abs.gov.au/websitedbs/d3310114.nsf/home/Census+data].
30. Proper KI, Cerin E, Brown WJ, Owen N: Sitting time and socio-
economic differences in overweight and obesity.  International
Journal of Obesity 2007, 31:169-76.
31. Australian Institute of Health and Welfare: Diabetes: Australian
Facts.  In Diabetes series no. 8. Cat No. CVD 40 Canberra AHIW; 2008. 
32. Sturm JW, Davis SM, O'Sullivan JG, Vedadhaghi ME, Donnan GA: The
Avoid Stroke as Soon as Possible (ASAP) general practice
stroke audit.  Medical Journal of Australia 2002, 176:312-6.
33. Siahpush M, Heller G, Singh G: Lower levels of occupation,
income and education are strongly associated with a longer
smoking duration: multivariate results from the 2001 Aus-
tralian National Drug Strategy Survey.  Public Health 2005,
119:1105-10.
34. Protheroe J, Fahey T, Montgomery AA, Peters TJ: The impact of
patients' preferences on the treatment of atrial fibrillation:
observational study of patient based decision analysis.  BMJ
2000, 320:1380-4.
35. Thomson RG, Eccles MP, Steen IN, Greenaway J, Stobbart L, Murtagh
MJ, May Cr: A patient decision aid to support shared decision-
making on antithrombotic treatment of patients with atrial
fibrillation: a randomized controlled trial.  Quality and safety in
Health Care 2007, 16:216-23.
36. McAlister FA, Man-Son-Hing M, Straus SE, Ghali WA, Anderson D,
Majumdar SR, Gibson P, Cox JL, Fradette M: Impact of a patient
decision-aid on care among patients with non-valvular atrial
fibrillation: a cluster randomised trial.  Canadian Medical Associ-
ation Journal 2005, 173:496-501.
37. Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA,
McBride R, Nasco E, Sherman DG, Talbert RL, Marler JR: Lessons
from the stroke prevention in atrial fibrillation trials.  Annals
of Internal Medicine 2003, 138:831-838.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2296/9/62/prepub